404 related articles for article (PubMed ID: 19397460)
1. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
Holland DP; Hamilton CD; Weintrob AC; Engemann JJ; Fortenberry ER; Peloquin CA; Stout JE
Pharmacotherapy; 2009 May; 29(5):503-10. PubMed ID: 19397460
[TBL] [Abstract][Full Text] [Related]
2. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T;
Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
[TBL] [Abstract][Full Text] [Related]
5. Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.
Tappero JW; Bradford WZ; Agerton TB; Hopewell P; Reingold AL; Lockman S; Oyewo A; Talbot EA; Kenyon TA; Moeti TL; Moffat HJ; Peloquin CA
Clin Infect Dis; 2005 Aug; 41(4):461-9. PubMed ID: 16028152
[TBL] [Abstract][Full Text] [Related]
6. Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.
Li J; Munsiff SS; Driver CR; Sackoff J
Clin Infect Dis; 2005 Jul; 41(1):83-91. PubMed ID: 15937767
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with reduced antituberculous serum drug concentrations in patients with HIV-TB coinfection.
Ahmed R; Cooper R; Foisy M; Der E; Kunimoto D
J Int Assoc Physicians AIDS Care (Chic); 2012; 11(5):273-6. PubMed ID: 22875581
[TBL] [Abstract][Full Text] [Related]
8. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
Jenny-Avital ER; Joseph K
Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
[TBL] [Abstract][Full Text] [Related]
9. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Mar; 51(10):214-5. PubMed ID: 11922192
[TBL] [Abstract][Full Text] [Related]
10. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.
Hamzeh FM; Benson C; Gerber J; Currier J; McCrea J; Deutsch P; Ruan P; Wu H; Lee J; Flexner C;
Clin Pharmacol Ther; 2003 Mar; 73(3):159-69. PubMed ID: 12621381
[TBL] [Abstract][Full Text] [Related]
11. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
Meloni M; Corti N; Müller D; Henning L; Gutteck U; von Braun A; Weber R; Fehr J
Swiss Med Wkly; 2015; 145():w14223. PubMed ID: 26700218
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis.
Weiner M; Benator D; Peloquin CA; Burman W; Vernon A; Engle M; Khan A; Zhao Z;
Clin Infect Dis; 2005 Nov; 41(9):1343-9. PubMed ID: 16206114
[TBL] [Abstract][Full Text] [Related]
13. Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak.
Spradling P; Drociuk D; McLaughlin S; Lee LM; Peloquin CA; Gallicano K; Pozsik C; Onorato I; Castro KG; Ridzon R
Clin Infect Dis; 2002 Nov; 35(9):1106-12. PubMed ID: 12384845
[TBL] [Abstract][Full Text] [Related]
14. Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis.
Narita M; Stambaugh JJ; Hollender ES; Jones D; Pitchenik AE; Ashkin D
Clin Infect Dis; 2000 May; 30(5):779-83. PubMed ID: 10816148
[TBL] [Abstract][Full Text] [Related]
15. Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis.
Burman W; Benator D; Vernon A; Khan A; Jones B; Silva C; Lahart C; Weis S; King B; Mangura B; Weiner M; El-Sadr W;
Am J Respir Crit Care Med; 2006 Feb; 173(3):350-6. PubMed ID: 16109981
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis and treatment of tuberculosis or Mycobacterium avium-intracellulare complex infection in HIV-infected patients].
Shirasaka T
Kekkaku; 2007 Nov; 82(11):845-8. PubMed ID: 18078110
[TBL] [Abstract][Full Text] [Related]
17. Serum concentrations of rifampicin and isoniazid in tuberculosis.
Seth V; Beotra A; Seth SD; Semwal OP; Kabra S; Jain Y; Mukhopadhya S
Indian Pediatr; 1993 Sep; 30(9):1091-8. PubMed ID: 8125594
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use.
Nettles RE; Mazo D; Alwood K; Gachuhi R; Maltas G; Wendel K; Cronin W; Hooper N; Bishai W; Sterling TR
Clin Infect Dis; 2004 Mar; 38(5):731-6. PubMed ID: 14986259
[TBL] [Abstract][Full Text] [Related]
19. Does AIDS impair the absorption of antituberculosis agents?
Taylor B; Smith PJ
Int J Tuberc Lung Dis; 1998 Aug; 2(8):670-5. PubMed ID: 9712282
[TBL] [Abstract][Full Text] [Related]
20. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study.
Matteelli A; Olliaro P; Signorini L; Cadeo G; Scalzini A; Bonazzi L; Caligaris S; Tomasoni L; Tebaldi A; Carosi G
Int J Tuberc Lung Dis; 1999 Nov; 3(11):1043-6. PubMed ID: 10587327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
